MX2024000520A - Uso de cepas bacterianas de lactobacillus paracasei en el tratamiento de recien nacidos. - Google Patents
Uso de cepas bacterianas de lactobacillus paracasei en el tratamiento de recien nacidos.Info
- Publication number
- MX2024000520A MX2024000520A MX2024000520A MX2024000520A MX2024000520A MX 2024000520 A MX2024000520 A MX 2024000520A MX 2024000520 A MX2024000520 A MX 2024000520A MX 2024000520 A MX2024000520 A MX 2024000520A MX 2024000520 A MX2024000520 A MX 2024000520A
- Authority
- MX
- Mexico
- Prior art keywords
- lactobacillus paracasei
- newborns
- treatment
- gastro
- bacterial strains
- Prior art date
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title abstract 4
- 230000001580 bacterial effect Effects 0.000 title 1
- 206010017964 Gastrointestinal infection Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 244000000010 microbial pathogen Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000018740A IT202100018740A1 (it) | 2021-07-15 | 2021-07-15 | Uso di ceppi di batteri Lactobacillus paracasei nel trattamento di neonati |
| PCT/IB2022/056538 WO2023286027A1 (en) | 2021-07-15 | 2022-07-15 | Use of lactobacillus paracasei bacterial strains in the treatment of newborns |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000520A true MX2024000520A (es) | 2024-01-31 |
Family
ID=78212428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000520A MX2024000520A (es) | 2021-07-15 | 2022-07-15 | Uso de cepas bacterianas de lactobacillus paracasei en el tratamiento de recien nacidos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240350567A1 (https=) |
| EP (1) | EP4370142A1 (https=) |
| JP (1) | JP2024525794A (https=) |
| KR (1) | KR20240038015A (https=) |
| CN (1) | CN119365205A (https=) |
| AU (1) | AU2022312760A1 (https=) |
| CA (1) | CA3222905A1 (https=) |
| IL (1) | IL309883A (https=) |
| IT (1) | IT202100018740A1 (https=) |
| MX (1) | MX2024000520A (https=) |
| WO (1) | WO2023286027A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118813489A (zh) * | 2024-08-29 | 2024-10-22 | 北京科拓恒通生物技术股份有限公司 | 一种用于缓解便秘和腹泻的益生菌后生元和制备方法及其用途 |
| CN120361059A (zh) * | 2025-06-30 | 2025-07-25 | 天津创源生物技术有限公司 | 一种副干酪乳酪杆菌iob413后生元在胃食管反流上的应用 |
| CN121533530A (zh) * | 2026-01-19 | 2026-02-17 | 内蒙古农业大学 | 一种副干酪乳酪杆菌-复合益生元复配制剂、制备方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8784798B2 (en) * | 2009-05-11 | 2014-07-22 | Nestec S.A. | Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders |
| IT201900000801A1 (it) * | 2019-01-18 | 2020-07-18 | Proge Farm Srl | Composizione comprendente batteri probiotici non vitali e suo uso in terapia |
| IT201900016865A1 (it) * | 2019-09-20 | 2021-03-20 | Sofar Spa | Composizioni a base di ceppi batterici e loro uso come antinfiammatori |
| IT201900016811A1 (it) * | 2019-09-20 | 2021-03-20 | Sofar Spa | Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali |
| IT201900020422A1 (it) * | 2019-11-05 | 2021-05-05 | Sofar Spa | Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine |
| IT202000012448A1 (it) * | 2020-05-26 | 2021-11-26 | Sofar Spa | Composizioni comprendenti un derivato della cannabis sativa e ceppi di batteri e loro uso terapeutico |
| IT202100008300A1 (it) * | 2021-04-01 | 2022-10-01 | Bll Invest S R L | Ceppi di batteri inattivati, quali batteri vitali ma non coltivabili, loro composizioni e loro uso |
-
2021
- 2021-07-15 IT IT102021000018740A patent/IT202100018740A1/it unknown
-
2022
- 2022-07-15 EP EP22751158.1A patent/EP4370142A1/en active Pending
- 2022-07-15 WO PCT/IB2022/056538 patent/WO2023286027A1/en not_active Ceased
- 2022-07-15 IL IL309883A patent/IL309883A/en unknown
- 2022-07-15 US US18/579,158 patent/US20240350567A1/en active Pending
- 2022-07-15 CN CN202280049761.9A patent/CN119365205A/zh active Pending
- 2022-07-15 KR KR1020247005329A patent/KR20240038015A/ko active Pending
- 2022-07-15 MX MX2024000520A patent/MX2024000520A/es unknown
- 2022-07-15 AU AU2022312760A patent/AU2022312760A1/en active Pending
- 2022-07-15 JP JP2024502018A patent/JP2024525794A/ja active Pending
- 2022-07-15 CA CA3222905A patent/CA3222905A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022312760A1 (en) | 2024-02-22 |
| US20240350567A1 (en) | 2024-10-24 |
| WO2023286027A1 (en) | 2023-01-19 |
| KR20240038015A (ko) | 2024-03-22 |
| IL309883A (en) | 2024-03-01 |
| CA3222905A1 (en) | 2023-01-19 |
| IT202100018740A1 (it) | 2023-01-15 |
| JP2024525794A (ja) | 2024-07-12 |
| CN119365205A (zh) | 2025-01-24 |
| EP4370142A1 (en) | 2024-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000520A (es) | Uso de cepas bacterianas de lactobacillus paracasei en el tratamiento de recien nacidos. | |
| Gaspar et al. | Bacteriocin production of the probiotic Lactobacillus acidophilus KS400 | |
| Singhal et al. | Evaluation of bile salt hydrolases, cholesterol-lowering capabilities, and probiotic potential of Enterococcus faecium isolated from rhizosphere | |
| Victor et al. | Probiotic properties of lactobacilli strains isolated from raw cow milk in the western highlands of Cameroon | |
| Asahara et al. | Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosaccharides | |
| CN112313325B (zh) | 新的植物乳杆菌菌株以及包含所述菌株的用于预防或治疗阴道炎的组合物 | |
| Monteagudo-Mera et al. | In vitro evaluation of physiological probiotic properties of different lactic acid bacteria strains of dairy and human origin | |
| Lahtinen et al. | Probiotics modulate the Bifidobacterium microbiota of elderly nursing home residents | |
| Bujalance et al. | A probiotic strain of Lactobacillus plantarum stimulates lymphocyte responses in immunologically intact and immunocompromised mice | |
| Pereira et al. | In vitro assessment of probiotic potential of Saccharomyces cerevisiae DABRP5 isolated from Bollo batter, a traditional Goan fermented food | |
| Barzegar et al. | Assessing the protection mechanisms against Enterobacter aerogenes by analyzing aggregation, adherence, antagonistic activity, and safety properties of potentially probiotic strain Lactobacillus brevis G145 | |
| Sabia et al. | Detection and partial characterization of a bacteriocin-like substance produced by Lactobacillus fermentum CS57 isolated from human vaginal secretions | |
| Hamdy et al. | Possible correlation between levansucrase production and probiotic activity of Bacillus sp. isolated from honey and honey bee | |
| Pessoa et al. | In vitro activity of lactobacilli with probiotic potential isolated from cocoa fermentation against Gardnerella vaginalis | |
| ATE302265T1 (de) | Einen lactobacillus-stamm enthaltende zusammensetzung und verwendungen davon | |
| Taweechotipatr et al. | Lactobacillus saerimneri and Lactobacillus ruminis: novel human-derived probiotic strains with immunomodulatory activities | |
| WO2018231992A3 (en) | METHODS OF USING LACTOBACILLUS PLANTARUM STRAINS TO PROTECT ANIMALS AGAINST PATHOGENIC BACTERIAL INFECTION | |
| DE60237645D1 (de) | Immunstimulierendes Mittel enthaltend eine Biomasse von methanotrophem Bakterium | |
| Mansour et al. | Inhibition of Clostridium difficile in mice using a mixture of potential probiotic strains Enterococcus faecalis NM815, E. faecalis NM915, and E. faecium NM1015: novel candidates to control C. difficile infection (CDI) | |
| Koll et al. | Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics | |
| EP2561880A3 (en) | Lactic acid bacteria as probiotic strains and compositions containing same | |
| Su et al. | Synergistic effect of green tea extract and probiotics on the pathogenic bacteria, Staphylococcus aureus and Streptococcus pyogenes | |
| Gautam et al. | Evaluation of probiotic potential of new bacterial strain, Lactobacillus spicheri G2 isolated from Gundruk | |
| US20130011374A1 (en) | Growth inhibition of microorganisms by lactic acid bacteria | |
| Daniele et al. | Curative effect of the probiotic strain Lactobacillus fermentum L23 in a murine model of vaginal infection by Gardnerella vaginalis |